AT403917B - Indolderivate - Google Patents

Indolderivate Download PDF

Info

Publication number
AT403917B
AT403917B AT0075293A AT75293A AT403917B AT 403917 B AT403917 B AT 403917B AT 0075293 A AT0075293 A AT 0075293A AT 75293 A AT75293 A AT 75293A AT 403917 B AT403917 B AT 403917B
Authority
AT
Austria
Prior art keywords
compound
formula
metabolically labile
oxy
physiologically acceptable
Prior art date
Application number
AT0075293A
Other languages
German (de)
English (en)
Other versions
ATA75293A (de
Original Assignee
Glaxo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Spa filed Critical Glaxo Spa
Publication of ATA75293A publication Critical patent/ATA75293A/de
Application granted granted Critical
Publication of AT403917B publication Critical patent/AT403917B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AT0075293A 1992-04-16 1993-04-15 Indolderivate AT403917B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929208492A GB9208492D0 (en) 1992-04-16 1992-04-16 Heterocyclic compounds

Publications (2)

Publication Number Publication Date
ATA75293A ATA75293A (de) 1997-11-15
AT403917B true AT403917B (de) 1998-06-25

Family

ID=10714220

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0075293A AT403917B (de) 1992-04-16 1993-04-15 Indolderivate

Country Status (41)

Country Link
US (4) US5373018A (cg-RX-API-DMAC7.html)
EP (1) EP0568136A1 (cg-RX-API-DMAC7.html)
JP (2) JPH0649027A (cg-RX-API-DMAC7.html)
KR (1) KR100264114B1 (cg-RX-API-DMAC7.html)
CN (1) CN1042331C (cg-RX-API-DMAC7.html)
AP (1) AP480A (cg-RX-API-DMAC7.html)
AT (1) AT403917B (cg-RX-API-DMAC7.html)
AU (1) AU666927B2 (cg-RX-API-DMAC7.html)
BE (1) BE1006343A5 (cg-RX-API-DMAC7.html)
BG (1) BG62136B1 (cg-RX-API-DMAC7.html)
BR (1) BR1100323A (cg-RX-API-DMAC7.html)
CA (3) CA2094075A1 (cg-RX-API-DMAC7.html)
CH (1) CH685630A5 (cg-RX-API-DMAC7.html)
CY (1) CY2038B1 (cg-RX-API-DMAC7.html)
CZ (1) CZ285799B6 (cg-RX-API-DMAC7.html)
DK (1) DK169890B1 (cg-RX-API-DMAC7.html)
ES (1) ES2105924B1 (cg-RX-API-DMAC7.html)
FI (1) FI106198B (cg-RX-API-DMAC7.html)
FR (1) FR2690919B1 (cg-RX-API-DMAC7.html)
GB (2) GB9208492D0 (cg-RX-API-DMAC7.html)
GE (1) GEP19991704B (cg-RX-API-DMAC7.html)
GR (1) GR1001619B (cg-RX-API-DMAC7.html)
HK (1) HK95797A (cg-RX-API-DMAC7.html)
HU (2) HU217964B (cg-RX-API-DMAC7.html)
IL (1) IL105412A (cg-RX-API-DMAC7.html)
IS (1) IS3994A (cg-RX-API-DMAC7.html)
IT (1) IT1265325B1 (cg-RX-API-DMAC7.html)
LU (1) LU88248A1 (cg-RX-API-DMAC7.html)
MX (1) MX9302195A (cg-RX-API-DMAC7.html)
MY (1) MY112232A (cg-RX-API-DMAC7.html)
NO (1) NO301879B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ247413A (cg-RX-API-DMAC7.html)
OA (1) OA10103A (cg-RX-API-DMAC7.html)
PL (1) PL176451B1 (cg-RX-API-DMAC7.html)
RO (1) RO113242B1 (cg-RX-API-DMAC7.html)
RU (1) RU2129544C1 (cg-RX-API-DMAC7.html)
SE (1) SE504336C2 (cg-RX-API-DMAC7.html)
SK (1) SK281941B6 (cg-RX-API-DMAC7.html)
TW (1) TW224457B (cg-RX-API-DMAC7.html)
WO (1) WO1993021153A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA932642B (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9304500D0 (en) * 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
US5519048A (en) * 1993-05-27 1996-05-21 Merrell Pharmaceuticals Inc. 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
JP3334805B2 (ja) * 1993-05-27 2002-10-15 メレルファーマスーティカルズ インコーポレイテッド ３−（インドール−３−イル）−プロペン酸誘導体類及びその製剤組成物
GB9319243D0 (en) * 1993-09-17 1993-11-03 Glaxo Spa Heterocyclic compounds
GB9321221D0 (en) * 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds
TW280819B (cg-RX-API-DMAC7.html) * 1993-11-17 1996-07-11 Sumitomo Pharma
US5563157B1 (en) * 1994-10-31 1999-02-02 Hoecst Marion Roussel Inc Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
GB9502695D0 (en) * 1995-02-11 1995-03-29 Glaxo Spa Pharmaceutical composition
GB9504361D0 (en) * 1995-03-04 1995-04-26 Glaxo Spa Heterocyclic compounds
WO1998011892A1 (en) * 1996-09-17 1998-03-26 The Regents Of The University Of California Positive ampa receptor modulation to enhance brain neurotrophic factor expression
EP0929521B1 (en) * 1996-09-30 2005-11-09 Aventis Pharmaceuticals Inc. Nmda (n-methyl-d-aspartate) antagonists
US5922752A (en) * 1997-06-11 1999-07-13 Hoechst Marion Roussell, Inc. NMDA (n-methyl-d-aspartate) antagonists
PT1421939E (pt) * 1998-03-26 2010-07-12 Astellas Pharma Inc Preparaã†o da libertaã†o sustentada de um composto de macrëlido como tracolimus
MXPA03000861A (es) * 2000-07-31 2004-04-05 Dainippon Pharmaceutical Co Remedios para la demencia que contienen derivados de 2-abril-8-oxodihidropurina como ingrediente activo.
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
EP1463714A4 (en) * 2001-12-10 2005-10-19 Amgen Inc VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS
PA8579701A1 (es) * 2002-08-23 2005-05-24 Pfizer Prod Inc Profarmaco inhibidor de beta-lactamasa
DE10306202A1 (de) 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
MXPA05012895A (es) * 2003-06-05 2006-02-22 Pfizer Prod Inc Profarmaco inhibidor de beta-lactamasa.
RU2247563C1 (ru) * 2003-06-16 2005-03-10 Пятигорская государственная фармацевтическая академия Способ получения твердой лекарственной формы, содержащей глюкозамина гидрохлорид
ATE473967T1 (de) * 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
EP1709004A2 (en) * 2003-12-29 2006-10-11 Sepracor Inc. Pyrrole and pyrazole daao inhibitors
RU2281755C2 (ru) * 2004-04-19 2006-08-20 Пятигорская государственная фармацевтическая академия Композиция - лекарственная форма противоартрозного средства глюкозамина гидрохлорида для ректального применения
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
MX2008000250A (es) 2005-07-06 2008-03-19 Sepracor Inc Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y
AU2007205114B2 (en) 2006-01-06 2012-11-08 Sunovion Pharmaceuticals Inc. Cycloalkylamines as monoamine reuptake inhibitors
CN101426372A (zh) 2006-01-06 2009-05-06 塞普拉柯公司 基于四氢萘酮的单胺再摄取抑制剂
PT2816024T (pt) 2006-03-31 2017-10-20 Sunovion Pharmaceuticals Inc Aminas quirais
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
KR20090111322A (ko) 2007-01-18 2009-10-26 세프라코 아이엔시. 디 아미노산 옥시다제의 억제제
US8669291B2 (en) 2007-05-31 2014-03-11 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
EP2407454A4 (en) * 2009-03-10 2012-05-30 Santen Pharmaceutical Co Ltd PROPHYLACTIC OR THERAPEUTIC AGENT FOR OPTICAL NERVE DISORDERS COMPRISING A DERIVATIVE OR SALT OF 4,6-DICHLORO-1H-INDOLE-2-CARBOXYLIC ACID AS ACTIVE INGREDIENT
US20110034434A1 (en) * 2009-08-07 2011-02-10 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
AU2015253099B2 (en) 2014-04-30 2019-07-18 National Chiao Tung University Use of known compounds as D-amino acid oxidase inhibitors
CN110234635B (zh) 2016-09-14 2023-03-10 宇凤·简·曾 作为d-胺基酸氧化酶(daao)抑制剂之新颖经取代苯并咪唑衍生物
MX393950B (es) 2017-06-12 2025-03-24 Glytech Llc Composicion y metodo para el tratamiento de la depresion y psicosis en humanos
CN112707874A (zh) * 2020-12-29 2021-04-27 广东中科药物研究有限公司 一种抗病毒化合物及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010971A (en) * 1960-08-04 1961-11-28 Smith Kline French Lab Cyclopropylamine derivatives and processes for their preparation
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
EP0396124A2 (en) * 1989-05-05 1990-11-07 G.D. Searle & Co. Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders
WO1992001670A1 (en) * 1990-07-16 1992-02-06 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
WO1992016205A2 (en) * 1991-03-18 1992-10-01 Warner-Lambert Company Novel derivatives of 2-carboxyndoles having pharmaceutical activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK500285A (da) * 1984-11-02 1986-05-03 Glaxo Group Ltd Cephalosporinantibiotika
US5145845A (en) * 1991-05-14 1992-09-08 Warner-Lambert Co. Substituted 2-carboxylindoles having pharmaceutical activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010971A (en) * 1960-08-04 1961-11-28 Smith Kline French Lab Cyclopropylamine derivatives and processes for their preparation
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
EP0396124A2 (en) * 1989-05-05 1990-11-07 G.D. Searle & Co. Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders
WO1992001670A1 (en) * 1990-07-16 1992-02-06 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
WO1992016205A2 (en) * 1991-03-18 1992-10-01 Warner-Lambert Company Novel derivatives of 2-carboxyndoles having pharmaceutical activity

Also Published As

Publication number Publication date
DK169890B1 (da) 1995-03-27
EP0568136A1 (en) 1993-11-03
GB9208492D0 (en) 1992-06-03
US5374648A (en) 1994-12-20
RU2129544C1 (ru) 1999-04-27
GEP19991704B (en) 1999-08-05
DK43193D0 (da) 1993-04-15
WO1993021153A1 (en) 1993-10-28
AU666927B2 (en) 1996-02-29
BG99111A (bg) 1995-05-31
SK124194A3 (en) 1995-05-10
DK43193A (da) 1993-10-17
CN1085212A (zh) 1994-04-13
IT1265325B1 (it) 1996-10-31
GB2266091B (en) 1995-08-09
NZ247413A (en) 1995-12-21
HU9402975D0 (en) 1995-02-28
SE9301241D0 (sv) 1993-04-15
CZ285799B6 (cs) 1999-11-17
US5374649A (en) 1994-12-20
HUT70526A (en) 1995-10-30
LU88248A1 (fr) 1994-03-01
CH685630A5 (fr) 1995-08-31
AP9300524A0 (en) 1993-04-30
HU217964B (hu) 2000-05-28
CA2094073A1 (en) 1993-10-17
HU211826A9 (en) 1995-12-28
JPH0649027A (ja) 1994-02-22
NO301879B1 (no) 1997-12-22
AU3692393A (en) 1993-10-21
TW224457B (cg-RX-API-DMAC7.html) 1994-06-01
SE9301241L (sv) 1993-10-17
KR100264114B1 (ko) 2000-11-01
IL105412A (en) 1998-02-22
CN1042331C (zh) 1999-03-03
ITRM930236A1 (it) 1994-10-15
NO943913D0 (no) 1994-10-14
NO943913L (no) 1994-12-14
US5510367A (en) 1996-04-23
BG62136B1 (bg) 1999-03-31
JPH07505407A (ja) 1995-06-15
RO113242B1 (ro) 1998-05-29
RU94045915A (ru) 1996-09-10
SE504336C2 (sv) 1997-01-13
HK95797A (en) 1997-08-08
IS3994A (is) 1993-10-17
FR2690919A1 (fr) 1993-11-12
GR1001619B (el) 1994-07-29
ES2105924A1 (es) 1997-10-16
FI944800A0 (fi) 1994-10-12
FI944800L (fi) 1994-10-12
CZ254394A3 (en) 1995-07-12
ITRM930236A0 (it) 1993-04-15
CY2038B1 (en) 1998-04-30
ZA932642B (en) 1994-01-10
AP480A (en) 1996-03-22
FR2690919B1 (fr) 1995-05-05
IL105412A0 (en) 1993-08-18
ES2105924B1 (es) 1998-07-01
GB2266091A (en) 1993-10-20
BR1100323A (pt) 2000-06-27
CA2094075A1 (en) 1993-10-17
BE1006343A5 (fr) 1994-07-26
ATA75293A (de) 1997-11-15
PL176451B1 (pl) 1999-05-31
GB9307808D0 (en) 1993-06-02
SK281941B6 (sk) 2001-09-11
MY112232A (en) 2001-05-31
FI106198B (fi) 2000-12-15
CA2094076A1 (en) 1993-10-17
OA10103A (en) 1996-12-18
MX9302195A (es) 1994-03-31
US5373018A (en) 1994-12-13

Similar Documents

Publication Publication Date Title
AT403917B (de) Indolderivate
DE69032020T2 (de) N-Substituierte 4-Pyrimidinamine und -Pyrimidindiamine, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE69014351T2 (de) Pyridincarbonsäureamid-Derivate und diese enthaltende pharmazeutische Zusammensetzungen.
DE68908040T2 (de) 3-(4-Piperidin)-5-(2-sulphonylaminoethyl)-indol-Derivate.
DE69927803T2 (de) Imidazo-pyridin verbindungen, die die sekretion von magensäure hemmen.
DE69325199T2 (de) Triazolopyridazine als Antiasthmatika
DE69015842T2 (de) Nicotinsäurederivate und diese enthaltende pharmazeutische Zusammensetzungen.
DE69304883T2 (de) Xanthin Derivate
DE69716062T2 (de) Benzofuran-derivate und deren verwendung
DE69110254T2 (de) Hydroxychinolonderivate.
EP1202969A2 (de) Biphenylderivate, ihre herstellung und ihre verwendung als mtp-inhibitor
DE69714265T2 (de) Tetrahydrochinolinderivate als eaa antagonisten
EP0546388A1 (de) Azaheterocyclylmethyl-chromane als Wirkstoffe zur Behandlung von Erkrankungen des Zentralnervensystems
DE3880396T2 (de) Zur Behandlung von neurodegenerativen Erkrankungen verwendbare Kynurensäurederivate.
DE69622731T2 (de) Tetrahydrochinoline als nmda antagonisten
EP0031080A1 (de) 2-Acylaminomethyl-1,4-benzodiazepine und deren Salze sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE69417235T2 (de) IMIDAZO[1,2-a]PYRAZIN-4-ON-DERIVATE ANTAGONISTEN DER AMPA UND NMDA REZEPTOREN
DE69118539T2 (de) Exzitatorische Aminosäureantagonisten
DE69508421T2 (de) SPIRO[HETEROZYCLISCHE-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZIN]-4'-ONE, IHRE HERSTELLUNG UND DIESE ENTHALTENDE ARZNEIMITTEL
JPH0372467A (ja) ピペラジン誘導体
DE60026883T2 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
WO1992014465A1 (de) Verwendung von anellierten tetrahydropyridinessigsäurederivaten für die behandlung neurologischer erkrankungen
DE69926632T2 (de) Tetrahydrochinolinderivate als glycinantagonisten
DE69300373T2 (de) (1H-Indol-1-yl)-2-(Amino)Acetamide und verwandte (1H-Indol-1-yl)-(Aminoalkyl)Amide, Zwischenprodukte, Verfahren zur Herstellung davon und ihre Verwendung als Arzneimittel.
US4933354A (en) 2-pyrrolidone-5-carboxylic acid compounds useful for the treatment of mental disorders

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee
ELJ Ceased due to non-payment of the annual fee